BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 65,000 Shares

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 65,000 shares of the stock in a transaction dated Thursday, April 13th. The stock was sold at an average price of C$7.70, for a total transaction of C$500,500.00.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Price Performance

BioSyent stock traded down C$0.18 during trading hours on Tuesday, hitting C$11.52. 395 shares of the company traded hands, compared to its average volume of 6,849. The firm has a market cap of C$133.52 million, a P/E ratio of 19.50 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. The firm’s 50-day simple moving average is C$11.06 and its two-hundred day simple moving average is C$10.29. BioSyent Inc. has a 1-year low of C$8.24 and a 1-year high of C$11.74.

BioSyent (CVE:RX) last released its earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, meeting the consensus estimate of C$0.13. The firm had revenue of C$8.95 million for the quarter, compared to analysts’ expectations of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. As a group, analysts forecast that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.